Axsome Therapeutics, Inc.
Pagina dedicata companiei Axsome Therapeutics, Inc. listata cu simbolul US.AXSM
Descriere companie[edit | ]
Axsome Therapeutics, Inc. (www.axsome.com) is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.
Grafic actiuni companie[edit | ]